Compare BlackRock TCP Capital Corp (TCPC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackRock TCP Capital Corp vs TransMedics Group Inc — how do they compare? BlackRock TCP Capital Corp trades at $4.01 (market cap $337.71M), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 8.1× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold BlackRock TCP Capital Corp for 88 Days and TransMedics Group Inc for 24 Days on average.
| TCPC | TMDX | |
|---|---|---|
Market Cap | $337.71M | $2.74B |
Volume | 436,109 | 949,331 |
Sector | Financials | Health |
52-Week High | $6.20 | $150.42 |
52-Week Low | $3.13 | $61.99 |
Typical Hold Time | 88 Days | 24 Days |
Enterprise Value | $1.09B | $3.13B |
Dividend Yield | 18.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCPC trades at $4.03, up 2.28% today, with a bullish technical signal from moving averages. The company reported negative revenue and net income for 2025 but beat Q2 2026 earnings expectations. Recent portfolio sales have reduced leverage and prompted a strategic review. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
The outlook remains cautious due to negative profitability metrics and declining revenue trends, though recent strategic moves and technical strength offer potential upside. Key risks include ongoing negative cash flow, class action lawsuits, and execution challenges in the private credit market.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
